Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com

Posted by on Apr 26th, 2023

Equities research analysts at StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO – Get Rating) (TSE:APS) in a note issued to investors on Wednesday. The firm set a “hold” rating on the biotechnology company’s stock.

Several other equities research analysts have also commented on the stock. Canaccord Genuity Group dropped their price target on shares of Aptose Biosciences from $13.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, March 27th. Royal Bank of Canada restated an “outperform” rating and issued a $5.00 price target on shares of Aptose Biosciences in a research note on Friday, March 24th.

Aptose Biosciences Price Performance

APTO opened at $0.48 on Wednesday. The firm has a market cap of $44.64 million, a price-to-earnings ratio of -1.07 and a beta of 1.54. Aptose Biosciences has a fifty-two week low of $0.43 and a fifty-two week high of $1.23. The company’s 50-day moving average price is $0.58 and its 200 day moving average price is $0.61.

Aptose Biosciences (NASDAQ:APTO – Get Rating) (TSE:APS) last announced its quarterly earnings results on Thursday, March 23rd. The biotechnology company reported ($0.11) EPS for the quarter, meeting the consensus estimate of ($0.11). During the same quarter last year, the business posted ($0.27) earnings per share. Research analysts anticipate that Aptose Biosciences will post -0.44 earnings per share for the current year.

Institutional Investors Weigh In On Aptose Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in APTO. Sequoia Financial Advisors LLC bought a new position in shares of Aptose Biosciences during the 1st quarter valued at $27,000. Toronto Dominion Bank raised its holdings in shares of Aptose Biosciences by 80.4% during the 3rd quarter. Toronto Dominion Bank now owns 43,851 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 19,541 shares in the last quarter. Cetera Advisors LLC raised its holdings in shares of Aptose Biosciences by 40.1% during the 4th quarter. Cetera Advisors LLC now owns 86,827 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 24,847 shares in the last quarter. Formidable Asset Management LLC bought a new position in shares of Aptose Biosciences during the 4th quarter valued at $52,000. Finally, Callan Capital LLC bought a new position in shares of Aptose Biosciences during the 4th quarter valued at $91,000. Hedge funds and other institutional investors own 26.60% of the company’s stock.

About Aptose Biosciences

(Get Rating)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Further Reading

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.